HMGB1/RAGE axis in tumor development: unraveling its significance

High mobility group protein 1 (HMGB1) plays a complex role in tumor biology. When released into the extracellular space, it binds to the receptor for advanced glycation end products (RAGE) located on the cell membrane, playing an important role in tumor development by regulating a number of biologic...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 14; p. 1336191
Main Authors Fan, Anqi, Gao, Mengxiang, Tang, Xuhuan, Jiao, Mengya, Wang, Chenchen, Wei, Yingying, Gong, Quan, Zhong, Jixin
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 01.03.2024
Subjects
development
HMGB1
HMGB1/RAGE axis
Oncology
RAGE
tumor
development
HMGB1
RAGE
HMGB1/RAGE axis
tumor
Online AccessGet full text

Cover

Abstract High mobility group protein 1 (HMGB1) plays a complex role in tumor biology. When released into the extracellular space, it binds to the receptor for advanced glycation end products (RAGE) located on the cell membrane, playing an important role in tumor development by regulating a number of biological processes and signal pathways. In this review, we outline the multifaceted functions of the HMGB1/RAGE axis, which encompasses tumor cell proliferation, apoptosis, autophagy, metastasis, and angiogenesis. This axis is instrumental in tumor progression, promoting tumor cell proliferation, autophagy, metastasis, and angiogenesis while inhibiting apoptosis, through pivotal signaling pathways, including MAPK, NF-κB, PI3K/AKT, ERK, and STAT3. Notably, small molecules, such as miRNA-218, ethyl pyruvate (EP), and glycyrrhizin exhibit the ability to inhibit the HMGB1/RAGE axis, restraining tumor development. Therefore, a deeper understanding of the mechanisms of the HMGB1/RAGE axis in tumors is of great importance, and the development of inhibitors targeting this axis warrants further exploration.
AbstractList High mobility group protein 1 (HMGB1) plays a complex role in tumor biology. When released into the extracellular space, it binds to the receptor for advanced glycation end products (RAGE) located on the cell membrane, playing an important role in tumor development by regulating a number of biological processes and signal pathways. In this review, we outline the multifaceted functions of the HMGB1/RAGE axis, which encompasses tumor cell proliferation, apoptosis, autophagy, metastasis, and angiogenesis. This axis is instrumental in tumor progression, promoting tumor cell proliferation, autophagy, metastasis, and angiogenesis while inhibiting apoptosis, through pivotal signaling pathways, including MAPK, NF-κB, PI3K/AKT, ERK, and STAT3. Notably, small molecules, such as miRNA-218, ethyl pyruvate (EP), and glycyrrhizin exhibit the ability to inhibit the HMGB1/RAGE axis, restraining tumor development. Therefore, a deeper understanding of the mechanisms of the HMGB1/RAGE axis in tumors is of great importance, and the development of inhibitors targeting this axis warrants further exploration.
High mobility group protein 1 (HMGB1) plays a complex role in tumor biology. When released into the extracellular space, it binds to the receptor for advanced glycation end products (RAGE) located on the cell membrane, playing an important role in tumor development by regulating a number of biological processes and signal pathways. In this review, we outline the multifaceted functions of the HMGB1/RAGE axis, which encompasses tumor cell proliferation, apoptosis, autophagy, metastasis, and angiogenesis. This axis is instrumental in tumor progression, promoting tumor cell proliferation, autophagy, metastasis, and angiogenesis while inhibiting apoptosis, through pivotal signaling pathways, including MAPK, NF-κB, PI3K/AKT, ERK, and STAT3. Notably, small molecules, such as miRNA-218, ethyl pyruvate (EP), and glycyrrhizin exhibit the ability to inhibit the HMGB1/RAGE axis, restraining tumor development. Therefore, a deeper understanding of the mechanisms of the HMGB1/RAGE axis in tumors is of great importance, and the development of inhibitors targeting this axis warrants further exploration.High mobility group protein 1 (HMGB1) plays a complex role in tumor biology. When released into the extracellular space, it binds to the receptor for advanced glycation end products (RAGE) located on the cell membrane, playing an important role in tumor development by regulating a number of biological processes and signal pathways. In this review, we outline the multifaceted functions of the HMGB1/RAGE axis, which encompasses tumor cell proliferation, apoptosis, autophagy, metastasis, and angiogenesis. This axis is instrumental in tumor progression, promoting tumor cell proliferation, autophagy, metastasis, and angiogenesis while inhibiting apoptosis, through pivotal signaling pathways, including MAPK, NF-κB, PI3K/AKT, ERK, and STAT3. Notably, small molecules, such as miRNA-218, ethyl pyruvate (EP), and glycyrrhizin exhibit the ability to inhibit the HMGB1/RAGE axis, restraining tumor development. Therefore, a deeper understanding of the mechanisms of the HMGB1/RAGE axis in tumors is of great importance, and the development of inhibitors targeting this axis warrants further exploration.
Author Jiao, Mengya
Fan, Anqi
Tang, Xuhuan
Zhong, Jixin
Wei, Yingying
Gong, Quan
Gao, Mengxiang
Wang, Chenchen
AuthorAffiliation 2 Department of Immunology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonostic Infectious Disease, Huazhong University of Science and Technology , Wuhan, Hubei , China
3 National Demonstration Center for Experimental Basic Medical Education, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , China
4 Department of Rheumatology and Immunology, Tongji Hospital, Huazhong University of Science and Technology , Wuhan, Hubei , China
5 Department of Immunology, School of Medicine, Yangtze University , Jingzhou, Hubei , China
1 College of Life Science, Yangtze University , Jingzhou, Hubei , China
AuthorAffiliation_xml – name: 3 National Demonstration Center for Experimental Basic Medical Education, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology , Wuhan , China
– name: 4 Department of Rheumatology and Immunology, Tongji Hospital, Huazhong University of Science and Technology , Wuhan, Hubei , China
– name: 5 Department of Immunology, School of Medicine, Yangtze University , Jingzhou, Hubei , China
– name: 2 Department of Immunology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonostic Infectious Disease, Huazhong University of Science and Technology , Wuhan, Hubei , China
– name: 1 College of Life Science, Yangtze University , Jingzhou, Hubei , China
Author_xml – sequence: 1
  givenname: Anqi
  surname: Fan
  fullname: Fan, Anqi
– sequence: 2
  givenname: Mengxiang
  surname: Gao
  fullname: Gao, Mengxiang
– sequence: 3
  givenname: Xuhuan
  surname: Tang
  fullname: Tang, Xuhuan
– sequence: 4
  givenname: Mengya
  surname: Jiao
  fullname: Jiao, Mengya
– sequence: 5
  givenname: Chenchen
  surname: Wang
  fullname: Wang, Chenchen
– sequence: 6
  givenname: Yingying
  surname: Wei
  fullname: Wei, Yingying
– sequence: 7
  givenname: Quan
  surname: Gong
  fullname: Gong, Quan
– sequence: 8
  givenname: Jixin
  surname: Zhong
  fullname: Zhong, Jixin
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38529373$$D View this record in MEDLINE/PubMed
BookMark eNp1kV1rFDEYhYNU2lr7A7yRufRmt0neTLLxRralbgsVQRR6FzL5WFNmkjWZKe2_N-tupRXMTb7OeQ4v5w06iCk6hN4RPAdYyDOfoplTTNmcAHAiySt0TCmwmWRwe_DsfIROS7nDdfEWEwyH6AgWLZUg4Bgtr76szsnZt-XqstEPoTQhNuM0pNxYd-_6tBlcHD82U8y6XkNcN2EsTQnrGHwwOhr3Fr32ui_udL-foB-fL79fXM1uvq6uL5Y3M8M4H2cLINQQ5gznnZNtK1thhKYWWo-FwK33YA3zBLz3XBhbJ-qwdJJLww3rPJyg6x3XJn2nNjkMOj-qpIP685DyWuk8BtM7Za2lEhNnyaJlHROdNpxKwUVrPbfeVtanHWszdYOzps6Ydf8C-vInhp9qne4VwZJTxlglfNgTcvo1uTKqIRTj-l5Hl6aiAGNgIJmAKn3_POxvylMJVSB2ApNTKdl5ZcKox5C22aGvoWrbuNo2rraNq33j1Un-cT7B_-_5DSoorqE
CitedBy_id crossref_primary_10_1016_j_placenta_2024_12_006
crossref_primary_10_1155_2024_5593203
crossref_primary_10_1021_acs_jmedchem_4c01912
crossref_primary_10_1186_s40364_025_00731_z
Cites_doi 10.1371/journal.pone.0084838
10.1111/j.1349-7006.2008.00893.x
10.1038/s41598-018-28023-7
10.3390/ijms21103613
10.21873/anticanres.12992
10.3389/fimmu.2022.931473
10.4103/jcrt.JCRT_180_18
10.1074/jbc.M111.277731
10.1016/j.tcb.2003.12.002
10.1186/s10020-018-0021-x
10.1159/000488340
10.1002/jcp.30125
10.1007/s11060-007-9488-y
10.1189/jlb.1104648
10.3390/medicines8040017
10.3892/or.2016.5181
10.1073/pnas.1615327114
10.1182/blood-2016-04-710632
10.1186/s13045-020-00950-x
10.3389/fimmu.2020.01455
10.1038/cdd.2009.149
10.1038/cddis.2011.36
10.3390/ijms13055982
10.3390/ijms23169327
10.1002/1878-0261.12851
10.1016/S0021-9258(18)42137-0
10.4149/neo_2020_200610N620
10.3892/ijo
10.1016/j.molcel.2018.03.030
10.4149/neo_2015_061
10.7150/jca.51049
10.1523/JNEUROSCI.4878-07.2008
10.1016/j.lfs.2019.117120
10.1002/cbin.12110
10.1080/14728222.2019.1676416
10.1080/21655979.2021.1972082
10.1158/1078-0432.CCR-19-4042
10.3390/ijms23136934
10.1002/jcp.28920
10.1152/ajpcell.00401.2005
10.1007/s11010-017-2968-2
10.1007/s00109-016-1435-y
10.1177/030089161109700211
10.1007/s11010-020-03928-y
10.1155/2016/6809703
10.3109/00016489.2015.1082192
10.1002/mc.22944
10.1016/j.acthis.2023.152028
10.1054/ijom.2002.0383
10.1038/s41419-019-1956-8
10.1084/jem.20030800
10.1038/onc.2012.49
10.1016/j.tox.2020.152668
10.1007/s10456-008-9093-5
10.1186/s12964-023-01172-7
10.1038/s41598-020-70137-4
10.1016/j.intimp.2021.107433
10.1016/j.heliyon.2020.e05672
10.3892/or
10.1016/j.mam.2014.05.001
10.1186/s13046-017-0519-z
10.3892/mmr.2015.4402
10.1016/j.pharmthera.2018.12.005
10.2353/ajpath.2007.070049
10.3892/etm.2014.2089
10.1002/jcb.28998
10.1016/j.biopha.2021.111504
10.1007/s00428-006-0359-2
10.1016/S0021-9258(18)42138-2
10.1016/j.tibs.2011.08.008
10.1158/0008-5472.CAN-14-1240
10.4161/cbt.5.1.2347
10.1002/ddr.21971
10.3892/or.2013.2595
10.1155/2022/4487435
10.1007/s00405-020-05789-z
10.1016/j.redox.2018.101083
10.1016/j.neuroscience.2012.10.023
10.3389/fmolb.2022.844618
10.1007/s13577-017-0182-x
10.3390/biom11101451
10.1074/jbc.M801622200
10.1007/s11010-014-1978-6
10.3164/jcbn.20-125
10.1186/s10020-023-00717-3
10.2147/CMAR.S252893
10.1200/JCO.2014.56.2728
10.2147/CMAR
10.1155/2013/713859
10.1002/tox.23107
10.1089/jir.2015.0082
10.1186/s40035-021-00271-0
10.1016/j.canlet.2012.02.014
10.1016/j.semcancer.2017.11.005
10.1002/iub.1379
10.1016/j.prp.2018.12.024
10.1016/j.ydbio.2005.12.029
10.1002/ptr.3018
10.1089/ars.2010.3666
10.2147/DDDT
10.1074/jbc.M801465200
10.1146/annurev-pathmechdis-012419-032711
10.1002/ptr.7385
10.1016/j.molimm.2013.07.008
10.1016/S0021-9258(17)36965-X
10.1186/1479-5876-7-17
10.1016/j.bbrc.2013.12.064
10.1146/annurev-med-041316-085215
10.1189/jlb.0806540
10.1080/15548627.2020.1752548
10.1007/s11010-020-04015-y
10.1371/journal.pone.0086903
10.1021/bi7003735
10.1111/jcmm.12577
10.1016/j.gde.2005.08.007
10.1189/jlb.1012519
10.3892/mmr.2017.7379
10.1007/s13277-015-3940-y
10.1038/s12276-022-00736-w
10.1186/s12885-022-09675-1
10.3390/biom11040526
10.1007/s12032-016-0869-y
10.1096/fj.202001183R
10.1038/s41419-018-1019-6
10.3892/or.2016.5317
10.3390/molecules25061320
10.1095/biolreprod.108.070243
10.1083/jcb.200911078
10.1002/iub.2383
10.1158/1078-0432.CCR-09-0155
10.1016/j.isci.2022.104872
10.1016/j.biopha.2023.115118
10.1038/s41419-018-0626-6
10.1038/srep32960
10.1038/onc.2012.494
10.1158/0008-5472.CAN-19-0542
10.1186/s12943-020-1138-4
10.2147/OTT
10.1016/j.mehy.2007.05.024
10.3892/ol
10.1016/S0140-6736(10)62307-0
10.1016/j.redox.2013.12.016
10.1038/onc.2010.261
10.3390/ijms21082961
10.1002/pros.20219
10.1016/j.molimm.2017.12.008
10.3390/ijms24098334
10.1002/eji.201646386
10.1016/j.canlet.2014.12.012
10.1021/acs.chemrestox.8b00376
10.1182/blood-2004-07-2551
10.1038/s41419-022-04670-7
10.1007/s00432-011-1067-0
10.1016/j.bbrc.2011.12.060
ContentType Journal Article
Copyright Copyright © 2024 Fan, Gao, Tang, Jiao, Wang, Wei, Gong and Zhong.
Copyright © 2024 Fan, Gao, Tang, Jiao, Wang, Wei, Gong and Zhong 2024 Fan, Gao, Tang, Jiao, Wang, Wei, Gong and Zhong
Copyright_xml – notice: Copyright © 2024 Fan, Gao, Tang, Jiao, Wang, Wei, Gong and Zhong.
– notice: Copyright © 2024 Fan, Gao, Tang, Jiao, Wang, Wei, Gong and Zhong 2024 Fan, Gao, Tang, Jiao, Wang, Wei, Gong and Zhong
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fonc.2024.1336191
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList

PubMed
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2234-943X
ExternalDocumentID oai_doaj_org_article_ddd2901ed1854b47bac6297675df6dfd
PMC10962444
38529373
10_3389_fonc_2024_1336191
Genre Journal Article
Review
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EJD
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c466t-8312c14ec66be955957c7a2d35f07705ff3dc4f13fff67cd619b09e969c6c4bf3
IEDL.DBID M48
ISSN 2234-943X
IngestDate Wed Aug 27 01:31:15 EDT 2025
Thu Aug 21 18:35:38 EDT 2025
Fri Jul 11 00:22:33 EDT 2025
Thu Apr 03 06:58:16 EDT 2025
Tue Jul 01 01:55:33 EDT 2025
Thu Apr 24 22:59:51 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords development
HMGB1
RAGE
HMGB1/RAGE axis
tumor
Language English
License Copyright © 2024 Fan, Gao, Tang, Jiao, Wang, Wei, Gong and Zhong.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c466t-8312c14ec66be955957c7a2d35f07705ff3dc4f13fff67cd619b09e969c6c4bf3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Yi Zhang, The First Affiliated Hospital of Zhengzhou University, China
Celio Geraldo Freire-de-Lima, Federal University of Rio de Janeiro, Brazil
Reviewed by: Armando Rojas, Catholic University of the Maule, Chile
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fonc.2024.1336191
PMID 38529373
PQID 3003439473
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_ddd2901ed1854b47bac6297675df6dfd
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10962444
proquest_miscellaneous_3003439473
pubmed_primary_38529373
crossref_citationtrail_10_3389_fonc_2024_1336191
crossref_primary_10_3389_fonc_2024_1336191
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-03-01
PublicationDateYYYYMMDD 2024-03-01
PublicationDate_xml – month: 03
  year: 2024
  text: 2024-03-01
  day: 01
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in oncology
PublicationTitleAlternate Front Oncol
PublicationYear 2024
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Awuah (B39) 2017; 114
Shang (B54) 2020; 241
Zhu (B94) 2016; 136
Shiau (B19) 2020; 10
Ott (B61) 2014; 2
Tang (B96) 2021; 12
Singh (B69) 2022; 83
Mo (B29) 2019; 234
Wang (B72) 2020; 13
Zhang (B50) 2020; 11
Cuervo (B126) 2004; 14
Dong (B53) 2019; 32
Donadelli (B135) 2011; 2
Xue (B9) 2020; 236
Kierdorf (B63) 2013; 94
Qian (B95) 2019; 58
Peng (B93) 2015; 12
Huang (B113) 2018; 53
Fritz (B64) 2011; 36
Mukherjee (B6) 2019; 79
Hiramoto (B117) 2021; 69
van Beijnum (B153) 2013; 32
Tang (B23) 2013; 2013
Yaser (B79) 2012; 13
Abe (B88) 2021; 8
Tang (B131) 2011; 15
Lei (B80) 2013; 228
Devis-Jauregui (B128) 2021; 17
Zhu (B152) 2015; 19
Starkova (B1) 2023; 24
Ishiguro (B121) 2005; 64
Choi (B125) 2011; 97
Fang (B26) 2020; 34
Chen (B146) 2014; 74
Taniguchi (B7) 2017; 31
Li Pomi (B22) 2022; 23
Rai (B78) 2012; 287
Elangovan (B102) 2012; 417
Ye (B89) 2022; 25
Wu (B120) 2021; 36
Sparvero (B68) 2009; 7
Chen (B104) 2022; 23
Pang (B115) 2017; 37
Zeh (B133) 2020; 26
Su (B150) 2022; 2022
Zhang (B147) 2021; 94
Li (B99) 2017; 36
Ma (B38) 2023; 21
Ren (B51) 2023; 29
Nemeth (B33) 2005; 105
Dong (B70) 2022; 13
Liu (B20) 2023; 48
Meng (B55) 2018; 94
Amornsupak (B118) 2022; 22
Hwang (B154) 2020; 25
Chavakis (B60) 2003; 198
Tian (B49) 2021; 450
Wen (B4) 2021; 476
Gu (B34) 2019; 11
Marme (B144) 2018; 41
van Beijnum (B10) 2008; 11
Zirkel (B28) 2018; 70
Zhang (B108) 2012; 27
Mol (B98) 2019; 23
Feng (B46) 2016; 36
Fujii (B137) 2008; 99
Gorecki (B42) 2021; 10
Kay (B76) 2016; 2016
Kang (B31) 2014; 40
Gil (B134) 2017; 34
Bassi (B86) 2008; 87
Zheng (B2) 2022; 9
Catena (B5) 2009; 80
Tang (B18) 2007; 81
Chen (B13) 2022; 54
Hudson (B77) 2008; 283
Tang (B119) 2012; 322
Zhang (B30) 2019; 120
Pergolizzi (B41) 2023; 125
Ahmed (B24) 2020; 14
Li (B127) 2020; 19
Zheng (B3) 2023; 165
Leitner (B52) 2019; 23
Gong (B112) 2013; 30
Huang (B141) 2018; 9
Xie (B65) 2008; 283
Voong (B8) 2021; 11
Guo (B142) 2019; 15
Lin (B90) 2012; 138
Cheng (B81) 2014; 443
Tang (B130) 2010; 190
Terada (B32) 2006; 291
Rojas (B21) 2016; 37
Yang (B11) 2005; 78
Lee (B27) 2018; 8
Zhang (B12) 2008; 70
Singh (B47) 2016; 46
Sturchler (B73) 2008; 28
Sasahira (B149) 2007; 450
Waghela (B75) 2021; 476
Angelopoulou (B87) 2016; 94
El-Far (B74) 2020; 21
Riuzzi (B122) 2007; 171
Sessa (B66) 2014; 9
Aucott (B43) 2018; 24
Wan (B105) 2017; 16
Pellegrini (B14) 2019; 196
Avila (B25) 2013; 8
Schmidt (B67) 1994; 269
Petrarolha (B151) 2020; 277
Chen (B123) 2021; 68
Chen (B15) 2020; 6
Hudson (B17) 2018; 69
Ma (B37) 2022; 13
Schmidt (B59) 1992; 267
Zhu (B114) 2015; 357
Tao (B107) 2019; 13
Stark (B45) 2016; 128
Mukubou (B136) 2010; 37
Yin (B36) 2020; 72
Tesarova (B57) 2015; 62
Ren (B156) 2021; 12
Zhang (B48) 2019; 10
Bianchi (B16) 2005; 15
Swami (B91) 2021; 11
Kim (B155) 2018; 38
Yen (B103) 2021; 138
Esmat (B106) 2006; 5
Wu (B138) 2018; 11
Chen (B111) 2014; 390
Kumar (B109) 2010; 24
Candolfi (B85) 2009; 15
Liu (B82) 2019; 42
Xie (B35) 2020; 12
Gao (B56) 2020; 21
Zhang (B116) 2018; 53
Neeper (B58) 1992; 267
He (B83) 2018; 9
Zhao (B139) 2013; 32
Dhumale (B92) 2015; 67
Qi (B143) 2022; 23
Rouhiainen (B40) 2016; 6
Chen (B110) 2022; 36
Tang (B129) 2010; 29
Kaufman (B100) 2015; 33
Ricciuti (B145) 2019; 56
Schliephake (B148) 2003; 32
Ibrahim (B62) 2013; 56
Wang (B84) 2015; 9
Wang (B97) 2019; 215
Dattilo (B71) 2007; 46
Park (B44) 2006; 290
Vincent (B101) 2011; 378
Chan (B140) 2020; 15
Kang (B132) 2009; 17
Li (B124) 2017; 431
References_xml – volume: 8
  year: 2013
  ident: B25
  article-title: Aberrant neural stem cell proliferation and increased adult neurogenesis in mice lacking chromatin protein HMGB2
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0084838
– volume: 99
  year: 2008
  ident: B137
  article-title: Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2008.00893.x
– volume: 8
  start-page: 4647
  year: 2018
  ident: B27
  article-title: HMGB2 is a novel adipogenic factor that regulates ectopic fat infiltration in skeletal muscles
  publication-title: Sci Rep
  doi: 10.1038/s41598-018-28023-7
– volume: 21
  start-page: 3613
  year: 2020
  ident: B74
  article-title: Role and mechanisms of RAGE-ligand complexes and RAGE-inhibitors in cancer progression
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21103613
– volume: 38
  year: 2018
  ident: B155
  article-title: Evodiamine suppresses survival, proliferation, migration and epithelial-mesenchymal transition of thyroid carcinoma cells
  publication-title: Anticancer Res
  doi: 10.21873/anticanres.12992
– volume: 13
  year: 2022
  ident: B70
  article-title: Pathophysiology of RAGE in inflammatory diseases
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.931473
– volume: 15
  year: 2019
  ident: B142
  article-title: Receptors for advanced glycation end products is associated with autophagy in the clear cell renal cell carcinoma
  publication-title: J Cancer Res Ther
  doi: 10.4103/jcrt.JCRT_180_18
– volume: 287
  year: 2012
  ident: B78
  article-title: Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M111.277731
– volume: 14
  year: 2004
  ident: B126
  article-title: Autophagy: in sickness and in health
  publication-title: Trends Cell Biol
  doi: 10.1016/j.tcb.2003.12.002
– volume: 24
  start-page: 19
  year: 2018
  ident: B43
  article-title: Ligation of free HMGB1 to TLR2 in the absence of ligand is negatively regulated by the C-terminal tail domain
  publication-title: Mol Med
  doi: 10.1186/s10020-018-0021-x
– volume: 41
  start-page: 164
  year: 2018
  ident: B144
  article-title: Tumor angiogenesis: A key target for cancer therapy
  publication-title: Oncol Res Treat
  doi: 10.1159/000488340
– volume: 236
  year: 2020
  ident: B9
  article-title: HMGB1 as a therapeutic target in disease
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.30125
– volume: 87
  start-page: 23
  year: 2008
  ident: B86
  article-title: HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration
  publication-title: J Neurooncol
  doi: 10.1007/s11060-007-9488-y
– volume: 78
  start-page: 1
  year: 2005
  ident: B11
  article-title: The cytokine activity of HMGB1
  publication-title: J Leukoc Biol
  doi: 10.1189/jlb.1104648
– volume: 8
  start-page: 17
  year: 2021
  ident: B88
  article-title: A unique anti-cancer 3-styrylchromone suppresses inflammatory response via HMGB1-RAGE signaling
  publication-title: Medicines (Basel)
  doi: 10.3390/medicines8040017
– volume: 27
  year: 2012
  ident: B108
  article-title: Inhibitory effects of ethyl pyruvate administration on human gastric cancer growth via regulation of the HMGB1-RAGE and Akt pathways in vitro and in vivo
  publication-title: Oncol Rep
  doi: 10.3892/or.2016.5181
– volume: 114
  year: 2017
  ident: B39
  article-title: Repair shielding of platinum-DNA lesions in testicular germ cell tumors by high-mobility group box protein 4 imparts cisplatin hypersensitivity
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.1615327114
– volume: 128
  year: 2016
  ident: B45
  article-title: Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice
  publication-title: Blood
  doi: 10.1182/blood-2016-04-710632
– volume: 13
  start-page: 116
  year: 2020
  ident: B72
  article-title: HMGB1 in inflammation and cancer
  publication-title: J Hematol Oncol
  doi: 10.1186/s13045-020-00950-x
– volume: 11
  year: 2020
  ident: B50
  article-title: Toll-like receptor 4 (TLR4)/opioid receptor pathway crosstalk and impact on opioid analgesia, immune function, and gastrointestinal motility
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2020.01455
– volume: 17
  year: 2009
  ident: B132
  article-title: The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival
  publication-title: Cell Death Differentiation
  doi: 10.1038/cdd.2009.149
– volume: 2
  start-page: e152
  year: 2011
  ident: B135
  article-title: Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2011.36
– volume: 13
  year: 2012
  ident: B79
  article-title: The Role of receptor for Advanced Glycation End Products (RAGE) in the proliferation of hepatocellular carcinoma
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms13055982
– volume: 23
  year: 2022
  ident: B22
  article-title: Role of HMGB1 in cutaneous melanoma: state of the art
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms23169327
– volume: 14
  start-page: 2994
  year: 2020
  ident: B24
  article-title: Targeting immunogenic cell death in cancer
  publication-title: Mol Oncol
  doi: 10.1002/1878-0261.12851
– volume: 267
  year: 1992
  ident: B59
  article-title: Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(18)42137-0
– volume: 68
  year: 2021
  ident: B123
  article-title: HMGB1-activated fibroblasts promote breast cancer cells metastasis via RAGE/aerobic glycolysis
  publication-title: Neoplasma
  doi: 10.4149/neo_2020_200610N620
– volume: 53
  year: 2018
  ident: B113
  article-title: Translationally controlled tumor protein affects colorectal cancer metastasis through the high mobility group box 1-dependent pathway
  publication-title: Int J Oncol
  doi: 10.3892/ijo
– volume: 70
  start-page: 730
  year: 2018
  ident: B28
  article-title: HMGB2 Loss upon Senescence Entry Disrupts Genomic Organization and Induces CTCF Clustering across Cell Types
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2018.03.030
– volume: 62
  year: 2015
  ident: B57
  article-title: RAGE and its ligands in cancer - culprits, biomarkers, or therapeutic targets
  publication-title: Neoplasma
  doi: 10.4149/neo_2015_061
– volume: 12
  year: 2021
  ident: B96
  article-title: High mobility group box 1 regulates gastric cancer cell proliferation and migration via RAGE-mTOR/ERK feedback loop
  publication-title: J Cancer
  doi: 10.7150/jca.51049
– volume: 28
  year: 2008
  ident: B73
  article-title: Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.4878-07.2008
– volume: 241
  year: 2020
  ident: B54
  article-title: HMGB1 was negatively regulated by HSF1 and mediated the TLR4/MyD88/NF-κB signal pathway in asthma
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2019.117120
– volume: 48
  year: 2023
  ident: B20
  article-title: HMGB1 in exosomes derived from gastric cancer cells induces M2-like macrophage polarization by inhibiting the NF-kappaB signaling pathway
  publication-title: Cell Biol Int
  doi: 10.1002/cbin.12110
– volume: 23
  year: 2019
  ident: B52
  article-title: Targeting toll-like receptor 4 to modulate neuroinflammation in central nervous system disorders
  publication-title: Expert Opin Ther Targets
  doi: 10.1080/14728222.2019.1676416
– volume: 12
  year: 2021
  ident: B156
  article-title: The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway
  publication-title: Bioengineered
  doi: 10.1080/21655979.2021.1972082
– volume: 26
  year: 2020
  ident: B133
  article-title: A randomized phase II preoperative study of autophagy inhibition with high-dose hydroxychloroquine and gemcitabine/nab-paclitaxel in pancreatic cancer patients
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-19-4042
– volume: 23
  year: 2022
  ident: B143
  article-title: Novel drugs with high efficacy against tumor angiogenesis
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms23136934
– volume: 234
  year: 2019
  ident: B29
  article-title: MicroRNA-329 upregulation impairs the HMGB2/β-catenin pathway and regulates cell biological behaviors in melanoma
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.28920
– volume: 290
  year: 2006
  ident: B44
  article-title: High mobility group box 1 protein interacts with multiple Toll-like receptors
  publication-title: Am J Physiology-Cell Physiol
  doi: 10.1152/ajpcell.00401.2005
– volume: 431
  start-page: 1
  year: 2017
  ident: B124
  article-title: HMGB1 attenuates TGF-beta-induced epithelial-mesenchymal transition of FaDu hypopharyngeal carcinoma cells through regulation of RAGE expression
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-017-2968-2
– volume: 94
  year: 2016
  ident: B87
  article-title: Pivotal role of high-mobility group box 1 (HMGB1) signaling pathways in glioma development and progression
  publication-title: J Mol Med (Berl)
  doi: 10.1007/s00109-016-1435-y
– volume: 97
  start-page: 196
  year: 2011
  ident: B125
  article-title: Interaction effect between the receptor for advanced glycation end products (RAGE) and high-mobility group box-1 (HMGB-1) for the migration of a squamous cell carcinoma cell line
  publication-title: Tumori
  doi: 10.1177/030089161109700211
– volume: 476
  year: 2021
  ident: B75
  article-title: AGE-RAGE synergy influences programmed cell death signaling to promote cancer
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-020-03928-y
– volume: 2016
  start-page: 1
  year: 2016
  ident: B76
  article-title: The role of AGE/RAGE signaling in diabetes-mediated vascular calcification
  publication-title: J Diabetes Res
  doi: 10.1155/2016/6809703
– volume: 136
  start-page: 87
  year: 2016
  ident: B94
  article-title: High mobility group box 1 (HMGB1) is upregulated by the Epstein-Barr virus infection and promotes the proliferation of human nasopharyngeal carcinoma cells
  publication-title: Acta Otolaryngol
  doi: 10.3109/00016489.2015.1082192
– volume: 58
  year: 2019
  ident: B95
  article-title: HMGB1-RAGE signaling facilitates Ras-dependent Yap1 expression to drive colorectal cancer stemness and development
  publication-title: Mol Carcinog
  doi: 10.1002/mc.22944
– volume: 125
  year: 2023
  ident: B41
  article-title: Expression and function of toll-like receptor 2 in vertebrate
  publication-title: Acta Histochemica
  doi: 10.1016/j.acthis.2023.152028
– volume: 32
  year: 2003
  ident: B148
  article-title: Prognostic relevance of molecular markers of oral cancer–a review
  publication-title: Int J Oral Maxillofac Surg
  doi: 10.1054/ijom.2002.0383
– volume: 10
  start-page: 724
  year: 2019
  ident: B48
  article-title: Dedifferentiation process driven by radiotherapy-induced HMGB1/TLR2/YAP/HIF-1α signaling enhances pancreatic cancer stemness
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-019-1956-8
– volume: 198
  year: 2003
  ident: B60
  article-title: The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment
  publication-title: J Exp Med
  doi: 10.1084/jem.20030800
– volume: 32
  year: 2013
  ident: B153
  article-title: Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1
  publication-title: Oncogene
  doi: 10.1038/onc.2012.49
– volume: 450
  year: 2021
  ident: B49
  article-title: Ozone exposure promotes pyroptosis in rat lungs via the TLR2/4-NF-κB-NLRP3 signaling pathway
  publication-title: Toxicology
  doi: 10.1016/j.tox.2020.152668
– volume: 11
  year: 2008
  ident: B10
  article-title: Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1)
  publication-title: Angiogenesis
  doi: 10.1007/s10456-008-9093-5
– volume: 21
  start-page: 144
  year: 2023
  ident: B38
  article-title: HMGB3 promotes the Malignant phenotypes and stemness of epithelial ovarian cancer through the MAPK/ERK signaling pathway
  publication-title: Cell Communication Signaling
  doi: 10.1186/s12964-023-01172-7
– volume: 10
  start-page: 13582
  year: 2020
  ident: B19
  article-title: Hepatocellular carcinoma-derived high mobility group box 1 triggers M2 macrophage polarization via a TLR2/NOX2/autophagy axis
  publication-title: Sci Rep
  doi: 10.1038/s41598-020-70137-4
– volume: 94
  year: 2021
  ident: B147
  article-title: HMGB1-TLR4-IL-23-IL-17A axis accelerates renal ischemia-reperfusion injury via the recruitment and migration of neutrophils
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2021.107433
– volume: 6
  year: 2020
  ident: B15
  article-title: HMGB1 as a potential biomarker and therapeutic target for severe COVID-19
  publication-title: Heliyon
  doi: 10.1016/j.heliyon.2020.e05672
– volume: 42
  year: 2019
  ident: B82
  article-title: Ethyl pyruvate suppresses the growth, invasion and migration and induces the apoptosis of non−small cell lung cancer cells via the HMGB1/RAGE axis and the NF−kappaB/STAT3 pathway
  publication-title: Oncol Rep
  doi: 10.3892/or
– volume: 40
  start-page: 1
  year: 2014
  ident: B31
  article-title: HMGB1 in health and disease
  publication-title: Mol Aspects Med
  doi: 10.1016/j.mam.2014.05.001
– volume: 36
  start-page: 51
  year: 2017
  ident: B99
  article-title: The long non-coding RNA TP73-AS1 modulates HCC cell proliferation through miR-200a-dependent HMGB1/RAGE regulation
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-017-0519-z
– volume: 12
  year: 2015
  ident: B93
  article-title: Effects of high−mobility group box 1 knockdown on proliferation, migration and invasion of the HONE−1 human nasopharyngeal carcinoma cell line
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2015.4402
– volume: 196
  year: 2019
  ident: B14
  article-title: HMGB1 and repair: focus on the heart
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2018.12.005
– volume: 171
  year: 2007
  ident: B122
  article-title: RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth
  publication-title: Am J Pathol
  doi: 10.2353/ajpath.2007.070049
– volume: 9
  year: 2015
  ident: B84
  article-title: Clinical and prognostic significance of high-mobility group box-1 in human gliomas
  publication-title: Exp Ther Med
  doi: 10.3892/etm.2014.2089
– volume: 120
  year: 2019
  ident: B30
  article-title: High-mobility group box 2 promoted proliferation of cervical cancer cells by activating AKT signaling pathway
  publication-title: J Cell Biochem
  doi: 10.1002/jcb.28998
– volume: 138
  start-page: 111504
  year: 2021
  ident: B103
  article-title: 4-Acetylantroquinonol B ameliorates nonalcoholic steatohepatitis by suppression of ER stress and NLRP3 inflammasome activation
  publication-title: BioMed Pharmacother
  doi: 10.1016/j.biopha.2021.111504
– volume: 450
  year: 2007
  ident: B149
  article-title: The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma
  publication-title: Virchows Arch
  doi: 10.1007/s00428-006-0359-2
– volume: 267
  year: 1992
  ident: B58
  article-title: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(18)42138-2
– volume: 36
  year: 2011
  ident: B64
  article-title: RAGE: a single receptor fits multiple ligands
  publication-title: Trends Biochem Sci
  doi: 10.1016/j.tibs.2011.08.008
– volume: 74
  year: 2014
  ident: B146
  article-title: RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-14-1240
– volume: 5
  start-page: 97
  year: 2006
  ident: B106
  article-title: Cytotoxicity of a natural anthraquinone (Aloin) against human breast cancer cell lines with and without ErbB-2: topoisomerase IIalpha coamplification
  publication-title: Cancer Biol Ther
  doi: 10.4161/cbt.5.1.2347
– volume: 83
  year: 2022
  ident: B69
  article-title: Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors
  publication-title: Drug Dev Res
  doi: 10.1002/ddr.21971
– volume: 30
  year: 2013
  ident: B112
  article-title: Invasion potential of H22 hepatocarcinoma cells is increased by HMGB1-induced tumor NF-kappaB signaling via initiation of HSP70
  publication-title: Oncol Rep
  doi: 10.3892/or.2013.2595
– volume: 2022
  start-page: 1
  year: 2022
  ident: B150
  article-title: HMGB1 promotes lymphangiogenesis through the activation of RAGE on M2 macrophages in laryngeal squamous cell carcinoma
  publication-title: Dis Markers
  doi: 10.1155/2022/4487435
– volume: 277
  year: 2020
  ident: B151
  article-title: Lymph node density as a predictive factor for worse outcomes in laryngeal cancer
  publication-title: Eur Arch Otorhinolaryngol
  doi: 10.1007/s00405-020-05789-z
– volume: 23
  start-page: 101083
  year: 2019
  ident: B98
  article-title: Advanced lipoxidation end products (ALEs) as RAGE binders: Mass spectrometric and computational studies to explain the reasons why
  publication-title: Redox Biol
  doi: 10.1016/j.redox.2018.101083
– volume: 228
  year: 2013
  ident: B80
  article-title: High-mobility group box1 protein promotes neuroinflammation after intracerebral hemorrhage in rats
  publication-title: Neuroscience
  doi: 10.1016/j.neuroscience.2012.10.023
– volume: 9
  year: 2022
  ident: B2
  article-title: Systematic analysis of expression profiles of HMGB family members for prognostic application in non-small cell lung cancer
  publication-title: Front Mol Biosci
  doi: 10.3389/fmolb.2022.844618
– volume: 31
  start-page: 1
  year: 2017
  ident: B7
  article-title: HMGB proteins and arthritis
  publication-title: Hum Cell
  doi: 10.1007/s13577-017-0182-x
– volume: 11
  year: 2021
  ident: B8
  article-title: Interactions of HMGB proteins with the genome and the impact on disease
  publication-title: Biomolecules
  doi: 10.3390/biom11101451
– volume: 283
  year: 2008
  ident: B65
  article-title: Structural basis for pattern recognition by the receptor for advanced glycation end products (RAGE)
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M801622200
– volume: 390
  year: 2014
  ident: B111
  article-title: The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-014-1978-6
– volume: 69
  start-page: 52
  year: 2021
  ident: B117
  article-title: Glycyrrhizin ameliorates melanoma cell extravasation into mouse lungs by regulating signal transduction through HMGB1 and its receptors
  publication-title: J Clin Biochem Nutr
  doi: 10.3164/jcbn.20-125
– volume: 29
  start-page: 117
  year: 2023
  ident: B51
  article-title: HMGB1 and Toll-like receptors: potential therapeutic targets in autoimmune diseases
  publication-title: Mol Med
  doi: 10.1186/s10020-023-00717-3
– volume: 12
  year: 2020
  ident: B35
  article-title: CircEPSTI1 promotes the progression of non-small cell lung cancer through miR-145/HMGB3 axis
  publication-title: Cancer Manage Res Volume
  doi: 10.2147/CMAR.S252893
– volume: 33
  year: 2015
  ident: B100
  article-title: Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.56.2728
– volume: 11
  year: 2019
  ident: B34
  article-title: HMGB3 silence inhibits breast cancer cell proliferation and tumor growth by interacting with hypoxia-inducible factor 1α
  publication-title: Cancer Manage Res Volume
  doi: 10.2147/CMAR
– volume: 2013
  start-page: 713859
  year: 2013
  ident: B23
  article-title: Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma
  publication-title: Mediators Inflammation
  doi: 10.1155/2013/713859
– volume: 36
  year: 2021
  ident: B120
  article-title: Verbascoside inhibits the epithelial-mesenchymal transition of prostate cancer cells through high-mobility group box 1/receptor for advanced glycation end-products/TGF-beta pathway
  publication-title: Environ Toxicol
  doi: 10.1002/tox.23107
– volume: 36
  year: 2016
  ident: B46
  article-title: TLR2 plays a critical role in HMGB1-induced glomeruli cell proliferation through the foxO1 signaling pathway in lupus nephritis
  publication-title: J Interferon Cytokine Res
  doi: 10.1089/jir.2015.0082
– volume: 10
  start-page: 47
  year: 2021
  ident: B42
  article-title: TLR2 and TLR4 in Parkinson’s disease pathogenesis: the environment takes a toll on the gut
  publication-title: Trans Neurodegeneration
  doi: 10.1186/s40035-021-00271-0
– volume: 322
  start-page: 98
  year: 2012
  ident: B119
  article-title: HMGB-1 induces cell motility and alpha5beta1 integrin expression in human chondrosarcoma cells
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2012.02.014
– volume: 56
  start-page: 87
  year: 2019
  ident: B145
  article-title: Enzymes involved in tumor-driven angiogenesis: A valuable target for anticancer therapy
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2017.11.005
– volume: 67
  year: 2015
  ident: B92
  article-title: Quercetin protects necrotic insult and promotes apoptosis by attenuating the expression of RAGE and its ligand HMGB1 in human breast adenocarcinoma cells
  publication-title: IUBMB Life
  doi: 10.1002/iub.1379
– volume: 215
  year: 2019
  ident: B97
  article-title: miR-129-5p attenuates cell proliferation and epithelial mesenchymal transition via HMGB1 in gastric cancer
  publication-title: Pathol Res Pract
  doi: 10.1016/j.prp.2018.12.024
– volume: 291
  start-page: 398
  year: 2006
  ident: B32
  article-title: Nucleosome regulator Xhmgb3 is required for cell proliferation of the eye and brain as a downstream target of Xenopus rax/Rx1
  publication-title: Dev Biol
  doi: 10.1016/j.ydbio.2005.12.029
– volume: 24
  year: 2010
  ident: B109
  article-title: Lucidone, a novel melanin inhibitor from the fruit of Lindera erythrocarpa Makino
  publication-title: Phytother Res
  doi: 10.1002/ptr.3018
– volume: 15
  year: 2011
  ident: B131
  article-title: High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress
  publication-title: Antioxid Redox Signal
  doi: 10.1089/ars.2010.3666
– volume: 13
  year: 2019
  ident: B107
  article-title: The molecular mechanisms of Aloin induce gastric cancer cells apoptosis by targeting High Mobility Group Box 1
  publication-title: Drug Des Devel Ther
  doi: 10.2147/DDDT
– volume: 283
  year: 2008
  ident: B77
  article-title: Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M801465200
– volume: 15
  year: 2020
  ident: B140
  article-title: Mitochondrial dynamics and its involvement in disease
  publication-title: Annu Rev Pathol
  doi: 10.1146/annurev-pathmechdis-012419-032711
– volume: 36
  year: 2022
  ident: B110
  article-title: Lucidone inhibits autophagy and MDR1 via HMGB1/RAGE/PI3K/Akt signaling pathway in pancreatic cancer cells
  publication-title: Phytother Res
  doi: 10.1002/ptr.7385
– volume: 56
  year: 2013
  ident: B62
  article-title: RAGE and TLRs: relatives, friends or neighbours
  publication-title: Mol Immunol
  doi: 10.1016/j.molimm.2013.07.008
– volume: 269
  year: 1994
  ident: B67
  article-title: The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(17)36965-X
– volume: 7
  start-page: 17
  year: 2009
  ident: B68
  article-title: RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation
  publication-title: J Transl Med
  doi: 10.1186/1479-5876-7-17
– volume: 443
  year: 2014
  ident: B81
  article-title: Ethyl pyruvate inhibits proliferation and induces apoptosis of hepatocellular carcinoma via regulation of the HMGB1-RAGE and AKT pathways
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2013.12.064
– volume: 69
  year: 2018
  ident: B17
  article-title: Targeting RAGE signaling in inflammatory disease
  publication-title: Annu Rev Med
  doi: 10.1146/annurev-med-041316-085215
– volume: 81
  year: 2007
  ident: B18
  article-title: Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1
  publication-title: J Leukoc Biol
  doi: 10.1189/jlb.0806540
– volume: 17
  year: 2021
  ident: B128
  article-title: Autophagy in the physiological endometrium and cancer
  publication-title: Autophagy
  doi: 10.1080/15548627.2020.1752548
– volume: 476
  year: 2021
  ident: B4
  article-title: The role of high mobility group protein B3 (HMGB3) in tumor proliferation and drug resistance
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-020-04015-y
– volume: 9
  year: 2014
  ident: B66
  article-title: The receptor for advanced glycation end-products (RAGE) is only present in mammals, and belongs to a family of cell adhesion molecules (CAMs)
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0086903
– volume: 46
  year: 2007
  ident: B71
  article-title: The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units
  publication-title: Biochemistry
  doi: 10.1021/bi7003735
– volume: 19
  year: 2015
  ident: B152
  article-title: Redox status of high-mobility group box 1 performs a dual role in angiogenesis of colorectal carcinoma
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.12577
– volume: 15
  start-page: 496
  year: 2005
  ident: B16
  article-title: HMG proteins: dynamic players in gene regulation and differentiation
  publication-title: Curr Opin Genet Dev
  doi: 10.1016/j.gde.2005.08.007
– volume: 94
  start-page: 55
  year: 2013
  ident: B63
  article-title: RAGE regulation and signaling in inflammation and beyond
  publication-title: J Leukoc Biol
  doi: 10.1189/jlb.1012519
– volume: 16
  year: 2017
  ident: B105
  article-title: Aloin promotes A549 cell apoptosis via the reactive oxygen species−mitogen activated protein kinase signaling pathway and p53 phosphorylation
  publication-title: Mol Med Rep
  doi: 10.3892/mmr.2017.7379
– volume: 37
  year: 2016
  ident: B21
  article-title: HMGB1 enhances the protumoral activities of M2 macrophages by a RAGE-dependent mechanism
  publication-title: Tumour Biol
  doi: 10.1007/s13277-015-3940-y
– volume: 54
  start-page: 91
  year: 2022
  ident: B13
  article-title: The mechanism of HMGB1 secretion and release
  publication-title: Exp Mol Med
  doi: 10.1038/s12276-022-00736-w
– volume: 22
  start-page: 578
  year: 2022
  ident: B118
  article-title: HMGB1 mediates invasion and PD-L1 expression through RAGE-PI3K/AKT signaling pathway in MDA-MB-231 breast cancer cells
  publication-title: BMC Cancer
  doi: 10.1186/s12885-022-09675-1
– volume: 11
  year: 2021
  ident: B91
  article-title: Inhibition of the receptor for advanced glycation end products enhances the cytotoxic effect of gemcitabine in murine pancreatic tumors
  publication-title: Biomolecules
  doi: 10.3390/biom11040526
– volume: 34
  start-page: 16
  year: 2017
  ident: B134
  article-title: The BAX gene as a candidate for negative autophagy-related genes regulator on mRNA levels in colorectal cancer
  publication-title: Med Oncol
  doi: 10.1007/s12032-016-0869-y
– volume: 34
  year: 2020
  ident: B26
  article-title: High mobility group box 2 regulates skeletal muscle development through ribosomal protein S6 kinase 1
  publication-title: FASEB J
  doi: 10.1096/fj.202001183R
– volume: 37
  year: 2010
  ident: B136
  article-title: The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation
  publication-title: Int J Oncol
  doi: 10.3892/ijo
– volume: 9
  start-page: 1004
  year: 2018
  ident: B141
  article-title: HMGB1 promotes ERK-mediated mitochondrial Drp1 phosphorylation for chemoresistance through RAGE in colorectal cancer
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-018-1019-6
– volume: 37
  year: 2017
  ident: B115
  article-title: High-mobility group box 1 is overexpressed in cervical carcinoma and promotes cell invasion and migration in vitro
  publication-title: Oncol Rep
  doi: 10.3892/or.2016.5317
– volume: 25
  year: 2020
  ident: B154
  article-title: Evodiamine mitigates cellular growth and promotes apoptosis by targeting the c-met pathway in prostate cancer cells
  publication-title: Molecules
  doi: 10.3390/molecules25061320
– volume: 80
  year: 2009
  ident: B5
  article-title: HMGB4, a novel member of the HMGB family, is preferentially expressed in the mouse testis and localizes to the basal pole of elongating spermatids1
  publication-title: Biol Reprod
  doi: 10.1095/biolreprod.108.070243
– volume: 190
  year: 2010
  ident: B130
  article-title: Endogenous HMGB1 regulates autophagy
  publication-title: J Cell Biol
  doi: 10.1083/jcb.200911078
– volume: 72
  year: 2020
  ident: B36
  article-title: CircMMP1 promotes the progression of glioma through miR-433/HMGB3 axis in vitro and in vivo
  publication-title: IUBMB Life
  doi: 10.1002/iub.2383
– volume: 15
  year: 2009
  ident: B85
  article-title: Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-0155
– volume: 25
  start-page: 104872
  year: 2022
  ident: B89
  article-title: Hypoxia-induced HMGB1 promotes glioma stem cells self-renewal and tumorigenicity via RAGE
  publication-title: iScience
  doi: 10.1016/j.isci.2022.104872
– volume: 165
  year: 2023
  ident: B3
  article-title: HMGB family proteins: Potential biomarkers and mechanistic factors in cardiovascular diseases
  publication-title: Biomedicine Pharmacotherapy
  doi: 10.1016/j.biopha.2023.115118
– volume: 9
  start-page: 648
  year: 2018
  ident: B83
  article-title: HMGB1 released by irradiated tumor cells promotes living tumor cell proliferation via paracrine effect
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-018-0626-6
– volume: 6
  year: 2016
  ident: B40
  article-title: HMGB4 is expressed by neuronal cells and affects the expression of genes involved in neural differentiation
  publication-title: Sci Rep
  doi: 10.1038/srep32960
– volume: 32
  year: 2013
  ident: B139
  article-title: Mitochondrial dynamics regulates migration and invasion of breast cancer cells
  publication-title: Oncogene
  doi: 10.1038/onc.2012.494
– volume: 79
  year: 2019
  ident: B6
  article-title: Targeting the high-mobility group box 3 protein sensitizes chemoresistant ovarian cancer cells to cisplatin
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-19-0542
– volume: 19
  start-page: 12
  year: 2020
  ident: B127
  article-title: Autophagy and autophagy-related proteins in cancer
  publication-title: Mol Cancer
  doi: 10.1186/s12943-020-1138-4
– volume: 11
  year: 2018
  ident: B138
  article-title: HMGB1/RAGE axis mediates the apoptosis, invasion, autophagy, and angiogenesis of the renal cell carcinoma
  publication-title: Onco Targets Ther
  doi: 10.2147/OTT
– volume: 70
  year: 2008
  ident: B12
  article-title: Inhibition of tumor angiogenesis by HMGB1 A box peptide
  publication-title: Med Hypotheses
  doi: 10.1016/j.mehy.2007.05.024
– volume: 23
  start-page: 128
  year: 2022
  ident: B104
  article-title: 4-Acetylantroquinonol B enhances cell death and inhibits autophagy by downregulating the PI3K/Akt/MDR1 pathway in gemcitabine-resistant pancreatic cancer cells
  publication-title: Oncol Lett
  doi: 10.3892/ol
– volume: 378
  year: 2011
  ident: B101
  article-title: Pancreatic cancer
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)62307-0
– volume: 2
  year: 2014
  ident: B61
  article-title: Role of advanced glycation end products in cellular signaling
  publication-title: Redox Biol
  doi: 10.1016/j.redox.2013.12.016
– volume: 29
  year: 2010
  ident: B129
  article-title: HMGB1 release and redox regulates autophagy and apoptosis in cancer cells
  publication-title: Oncogene
  doi: 10.1038/onc.2010.261
– volume: 21
  year: 2020
  ident: B56
  article-title: Glycyrrhizin Inhibits PEDV Infection and Proinflammatory Cytokine Secretion via the HMGB1/TLR4-MAPK p38 Pathway
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms21082961
– volume: 53
  year: 2018
  ident: B116
  article-title: High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE/NF-kappaB signaling pathway
  publication-title: Int J Oncol
  doi: 10.3892/ijo
– volume: 64
  start-page: 92
  year: 2005
  ident: B121
  article-title: Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development
  publication-title: Prostate
  doi: 10.1002/pros.20219
– volume: 94
  start-page: 7
  year: 2018
  ident: B55
  article-title: The protective effect of dexmedetomidine on LPS-induced acute lung injury through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR pathways
  publication-title: Mol Immunol
  doi: 10.1016/j.molimm.2017.12.008
– volume: 24
  year: 2023
  ident: B1
  article-title: Structure and functions of HMGB2 protein
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms24098334
– volume: 46
  year: 2016
  ident: B47
  article-title: HMGB1 facilitates hypoxia-induced vWF upregulation through TLR2-MYD88-SP1 pathway
  publication-title: Eur J Immunol
  doi: 10.1002/eji.201646386
– volume: 357
  year: 2015
  ident: B114
  article-title: High-mobility group box 1: a novel inducer of the epithelial-mesenchymal transition in colorectal carcinoma
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2014.12.012
– volume: 32
  year: 2019
  ident: B53
  article-title: Polychlorinated biphenyl quinone induces caspase 1-mediated pyroptosis through induction of pro-inflammatory HMGB1-TLR4-NLRP3-GSDMD signal axis
  publication-title: Chem Res Toxicol
  doi: 10.1021/acs.chemrestox.8b00376
– volume: 105
  year: 2005
  ident: B33
  article-title: Hmgb3 deficiency deregulates proliferation and differentiation of common lymphoid and myeloid progenitors
  publication-title: Blood
  doi: 10.1182/blood-2004-07-2551
– volume: 13
  start-page: 263
  year: 2022
  ident: B37
  article-title: HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
  publication-title: Cell Death Dis 13
  doi: 10.1038/s41419-022-04670-7
– volume: 138
  start-page: 11
  year: 2012
  ident: B90
  article-title: Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma
  publication-title: J Cancer Res Clin Oncol
  doi: 10.1007/s00432-011-1067-0
– volume: 417
  year: 2012
  ident: B102
  article-title: Targeting receptor for advanced glycation end products (RAGE) expression induces apoptosis and inhibits prostate tumor growth
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2011.12.060
SSID ssj0000650103
Score 2.414802
SecondaryResourceType review_article
Snippet High mobility group protein 1 (HMGB1) plays a complex role in tumor biology. When released into the extracellular space, it binds to the receptor for advanced...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1336191
SubjectTerms development
HMGB1
HMGB1/RAGE axis
Oncology
RAGE
tumor
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8NAEF7Eg3gR39YXK3gSYvPYR-KtFW0R6kEUvC3ZFxY0kTYFf74zTVpbEb14zW42u99Mdmcyk28IOefeWh2lJvBGhgGTkgc6Z3kApkQkUuuFtvgdcnAv-k_s7pk_L5T6wpywmh64Bq5trcVQn7NwsDDNpM6NiDOkIIGBrLe4-8KZt-BM1XswxwIGdRgTvLCs7csCGQtjdgleGXgN0dJBNOXr_8nI_J4ruXD43G6SjcZqpJ16tltkxRXbZG3QxMV3SKc_6HWj9kOnd0Pzj-GYDgtaTd7KEbVfSUFXdFJgsSH8AZ0OqzHF3A3MFELB75Kn25vH637QFEcIDBOiCtIkik3EnBFCO6SR49LIPLYJ96GUIfc-sYb5KPHeC2ksLFmHmctEZoRh2id7ZLUoC3dAKPiAzGjHUsMlViLOwSZhGgbJrXahjFsknCGlTMMcjgUsXhV4EAiuQnAVgqsacFvkYn7Le02b8VvnLsI_74iM19MLoAeq0QP1lx60yNlMeAreEAx75IUrJ2OVIAdPksHKWmS_Fub8UUnKwd7BlnRJzEtzWW4phi9TFu4InD-wjdjhf8z-iKwjInVy2zFZrUYTdwLWTqVPp4r9CStb_Ts
  priority: 102
  providerName: Directory of Open Access Journals
Title HMGB1/RAGE axis in tumor development: unraveling its significance
URI https://www.ncbi.nlm.nih.gov/pubmed/38529373
https://www.proquest.com/docview/3003439473
https://pubmed.ncbi.nlm.nih.gov/PMC10962444
https://doaj.org/article/ddd2901ed1854b47bac6297675df6dfd
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS-NAEF9EQXw59NS76ikr-HQQzcd-JAfHUQ9tEXoPYqFvS_brLGiibQr63zuTpPUq5R58yUOym2RndrK_2Zn8hpBT7q3VUWoCb2QYMCl5oHOWBwAlIpFaL7TFfcjBH9EfsusRH62ReXmrVoDTla4d1pMaTu7Pnp9efoHB_0SPE9bbc18WSEYYszNwuMAhAGdoAxYmiXY6aNF-82HmWNWgiW2u7rm0OtUk_quQ5_sEyn9WpKtt8qmFkrTb6H6HrLniM9kctMHyXdLtD3oX0flNt3dJ8-fxlI4LWs0eygm1b5lCP-iswApE-Fc6HVdTigkdmD6Es2GPDK8ub3_3g7ZiQmCYEFWQJlFsIuaMENohtxyXRuaxTbgPpQy594k1zEeJ915IY2HIOsxcJjIjDNM-2SfrRVm4r4SCY8iMdiw1XGJ54hyACtNwk9xqF8q4Q8K5pJRp6cSxqsW9ArcChatQuAqFq1rhdsj3RZfHhkvjf40vUPyLhkiDXZ8oJ39Va1XKWotxYGcBdTDNpM6NiDPkp4FZZr3tkJO58hSYDcZC8sKVs6lKkJgnyWBkHfKlUebiUUnKAQThlXRJzUvvsnylGN_V1NwReIQAmNjBx7seki2UQ5Pn9o2sV5OZOwLgU-njesMAjr1RdFxP7Vc1lAUq
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HMGB1%2FRAGE+axis+in+tumor+development%3A+unraveling+its+significance&rft.jtitle=Frontiers+in+oncology&rft.au=Fan%2C+Anqi&rft.au=Gao%2C+Mengxiang&rft.au=Tang%2C+Xuhuan&rft.au=Jiao%2C+Mengya&rft.date=2024-03-01&rft.pub=Frontiers+Media+S.A&rft.eissn=2234-943X&rft.volume=14&rft_id=info:doi/10.3389%2Ffonc.2024.1336191&rft.externalDocID=PMC10962444
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon